TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03141385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
Study: NCT01548560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Film
Description: Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Film
Description: Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapivirine Vaginal Film
Description: Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Gel
Description: Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Gel
Description: Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapivirine Vaginal Gel
Description: Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
Study: NCT03081754

Intervention type: RADIATION
Intervention: Doppler velocimetry
Description: Doppler studies were performed within the last week before delivery using a 3.5-Mhz transducer, all measurements were performed with the mothers in a semi recumbent position. Color-flow imaging was used to visualize the ascending branch of the uterine arteries. Pulsed Doppler velocimetry was performed with a sample volume of 5 mm.

Intervention type: RADIATION
Intervention: Doppler velocimetry
Description: Doppler studies were performed within the last week before delivery using a 3.5-Mhz transducer, all measurements were performed with the mothers in a semi recumbent position. Color-flow imaging was used to visualize the ascending branch of the uterine arteries. Pulsed Doppler velocimetry was performed with a sample volume of 5 mm.
Study: NCT04259515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Del Nido
Description: Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buckberg
Description: Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
Study: NCT01821287

Intervention type: OTHER
Intervention: CHD
Description: The study is not providing an intervention but rather is observational/studying factors that could contribute to nutritional failure in single ventricle CHD infants
Study: NCT00732225

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DisCoVisc
Description: DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuoVisc
Description: DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioVisc
Description: BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healon5
Description: Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amvisc Plus
Description: Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
Study: NCT00585377

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab and Erlotinib
Description: Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days
Study: NCT04003467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP05
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP05
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP05
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP05
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of EBP05
Description: tablets
Study: NCT03631992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Sweet
Description: Children in the experimental group get repeated exposure to lower sweet snacks and mothers get education lessons on dental care, reading food labels, portion size, and nutrition.
Study: NCT01098097

Intervention type: BIOLOGICAL
Intervention: Peginterferon alpha
Description: Peginterferon alpha given in combination with ribavirin according to local labeling guidelines

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin given in combination with peginterferon alpha according to local labeling guidelines
Study: NCT04175626

Intervention type: DEVICE
Intervention: Orsiro DES
Description: Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
Study: NCT03784560

Intervention type: OTHER
Intervention: The Psychomotor Vigilance Task (PVT)
Description: PVT has emerged as one of the most widely used tools to assess vigilant attention. Vigilance can be defined as sustained attention and tonic alertness. In sleep deprived individuals, vigilance is the component of cognition that is most consistently and dramatically affected. The PVT is a reaction-time test that allows the collection of a large amount of data in a relatively short period of time. These characteristics increase the sensitivity of the test to detect even small changes in vigilant attention, which can wax and wane within seconds.

Intervention type: OTHER
Intervention: Epworth Sleepiness Scale
Description: Epworth Sleepiness Scale a set of questions that assess excessive daytime sleepiness during professional activities and vacations.~This scale was designed to assess the efficiency of sleep apnea treatments. It is also used for the subjective sleepiness assessment based on the likelihood of falling asleep in different everyday life situations. This results in an overall score.

Intervention type: OTHER
Intervention: Karolinska sleeping scale
Description: The KSS is assumed to be an ordinal scale with a unitary structure. KSS scores may require standardization to control for differences between subjects. The changes observed in the EEG/EOG with drowsiness do not usually appear until KSS scores reach 7 and higher. Lower KSS scores (\<5) may reflect differences in the subjective awareness of fatigue as much, or more than, levels of drowsiness.~Higher KSS scores (7+) may refer more specifically to the state of drowsiness because the subject may then have experienced involuntary dozing behavior, with lapsing episodes and brief loss of awareness of the here-and-now, followed by arousal and the return of awareness, including some awareness of recently having dozed off

Intervention type: OTHER
Intervention: Trail making test
Description: Most variants of this test, which was apparently introduced in 1938 by Partington (Partington \& Leiter, 1949), have at least two conditions. In condition A the participant is to draw lines to connect circled numbers in a numerical sequence (i.e., 1-2-3, etc.) as rapidly as possible. In condition B the participant is to draw lines to connect circled numbers and letters in an alternating numeric and alphabetic sequence (i.e., 1-A-2-B, etc.) as rapidly as possible.
Study: NCT02067117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC FLU® Injection, GC FLU® Pre-filled Syringe Injection
Study: NCT05068245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preselected classical music
Description: Preselected classical music
Study: NCT03343457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Study: NCT02924064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin ≥ 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ≥ 1000 mg
Study: NCT03297723

Intervention type: OTHER
Intervention: Therapeutic education Programm
Description: Intervention will include:~* an identification of educational needs and expectations,~* a bilateral agreement between patient and medical staff on the priority skills acquirement,~* a structured educational activities tailored to the patient's need.~* the making of an educational record.
Study: NCT03631992

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Regular Sweet
Description: Children in sham comparator get typical snacks and mothers get education lessons on portion size, physical activity, sleep, and screen time.
Study: NCT03056092

Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal ranibizumab
Description: Patients will be treated with intravitreal ranibizumab and have their aqueous humor obtained for cytokine analysis at every visit that an intravitreal injection is done
Study: NCT01942837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide, formerly known as MDV3100, is a rationally-designed second generation AR inhibitor which functions by blocking several steps in the AR signaling cascade. Enzalutamide competitively binds the AR with great potency. Additionally, enzalutamide inhibits nuclear translocation of activated AR and inhibits the association of activated AR with DNA.
Study: NCT02267551

Intervention type: OTHER
Group type: OTHER
Intervention: Mimic dv-Trainer

Intervention type: OTHER
Group type: OTHER
Intervention: daVinci Skills Simulator
Study: NCT01798251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: capecitabine 850mg/m2 bid, d1-14, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine 850mg/m2 bid, d1-14, every 3 weeks
Study: NCT03326453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini dental implant
Description: titanium mini dental implant which diameter less than 3 mm
Study: NCT00449553

Intervention type: DRUG
Intervention: Pioglitazone and sulphonylurea
Description: Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.

Intervention type: DRUG
Intervention: Pioglitazone and sulphonylurea
Description: Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.

Intervention type: DRUG
Intervention: Pioglitazone and metformin
Description: Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.

Intervention type: DRUG
Intervention: Pioglitazone and metformin
Description: Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
Study: NCT00648830

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Single-dose of Clarithromycin 250 mg oral immediate-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: single-dose 250 mg immediate-release oral tablets
Study: NCT02534038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVP-786
Description: d6-DM/Q

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT02493543

Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection from the subject's arm

Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection from the subject's arm
Study: NCT02585479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirarubicin
Description: 1. Pirarubicin 30mg/m2 intravenously~2. Pirarubicin17mg/m2 are infused through the right and left hepatic arteries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirarubicin
Description: 1. Pirarubicin 30mg/m2 intravenously~2. Pirarubicin17mg/m2 are infused through the right and left hepatic arteries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 1. Oxaliplatin 100 mg/m2 intravenously~2. Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 1. Oxaliplatin 100 mg/m2 intravenously~2. Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipiodol
Description: Lipiodol 5-10ml infused through the right and left hepatic arteries

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam
Description: Hepatic artery embolization with Gelfoam.
Study: NCT04658082

Intervention type: DEVICE
Group type: OTHER
Intervention: H.G.R (GWave) non-invasive glucometer
Description: Glucose tolerance test
Study: NCT03377426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS228
Description: LYS228 IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care therapy
Description: IV infusion of standard of care antibiotics
Study: NCT01355653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermal therapy
Description: heat therapy device, topical, two applications, at 0-3 hours and 4-6 hours on treatment day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: marketed heatwrap
Description: heatwrap, topical, one time application, 8 hour duration
Study: NCT02216357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifetroban, Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Oral Capsule
Study: NCT03005964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM001 Cream, 7.5%
Description: Active Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Placebo
Study: NCT04428125

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Scan of Thoracic outlet region
Description: Both groups will undergo Magnetic Resonance Scan of cervicothoracobrachial region in order to study the anatomy of this region.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Scan of Thoracic outlet region
Description: Both groups will undergo Magnetic Resonance Scan of cervicothoracobrachial region in order to study the anatomy of this region.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex Ultrasound assessment of Upper limbs
Description: Both groups will undergo Duplex Ultrasound assessment of Upper limbs, in order to study diameters and flow of the vascular system of the upper limbs.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex Ultrasound assessment of Upper limbs
Description: Both groups will undergo Duplex Ultrasound assessment of Upper limbs, in order to study diameters and flow of the vascular system of the upper limbs.
Study: NCT03275844

Intervention type: PROCEDURE
Intervention: Physical activity assessment
Description: Assessment of Moderate-to-vigorous physical activity

Intervention type: PROCEDURE
Intervention: Physical activity assessment
Description: Assessment of Moderate-to-vigorous physical activity
Study: NCT02628912

Intervention type: OTHER
Intervention: blood draw

Intervention type: BEHAVIORAL
Intervention: study questionnaire

Intervention type: OTHER
Intervention: cardiopulmonary exercise testing (CPET)

Intervention type: OTHER
Intervention: DXA (dual-energy x-ray absorptiometry) scan
Study: NCT00945958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC0913
Description: One drop of SPARC0913 in affected eye once daily for 24 weeks
Study: NCT01635166

Intervention type: DEVICE
Group type: OTHER
Intervention: Delta Motion
Description: A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement.
Study: NCT00112996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid
Description: Oral two 300 mg ALA sustained release tablets initiated 4 days after last dose of platinum and discontinued 2 days before next scheduled platinum dose, continued for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally two similar color and sized placebo control tablets three times a day continued for 24 weeks.
Study: NCT04469907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977
Description: Participants will receive a single oral dose of AZD9977 under fasted conditions.
Study: NCT02501291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study: NCT00473564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: da Vinci® Robotic System
Description: Head and Neck Surgery using the da Vinci® Robotic System
Study: NCT00615303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone
Description: 2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day. The colonoscopic examination was recorded

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day
Study: NCT01198795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.
Study: NCT03038100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 of each 21-day cycle for a total of 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 of each 21-day cycle for a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab Placebo
Description: Placebo matching to atezolizumab on Day 1 of each 21-day cycle
Study: NCT03580811

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant &ADMG
Description: A dental implant will be placed and the buccal soft tissue will be grafted using ADMG .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant &ADMG
Description: A dental implant will be placed and the buccal soft tissue will be grafted using ADMG .
Study: NCT03993821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burosumab
Description: Burosumab, the investigational product, is a recombinant human IgG1 monoclonal antibody targeting FGF23. It is supplied as a sterile, clear, colorless and preservative-free solution and is administered via subcutaneous injection.
Study: NCT01090427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab - Half-Standard Dosage
Description: Ustekinumab 0.375 mg/kg, 22.5 mg, or 45 mg based on body weight, administered subcutaneously (under the skin) at Weeks 0, 4, 16, 28, and 40.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab - Standard Dosage
Description: Ustekinumab 0.75 mg/kg, 45 mg, or 90 mg based on body weight administered subcutaneously at Weeks 0, 4, 16, 28, and 40.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.
Study: NCT01154010

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEMF
Description: ActiPatch will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PEMF Placebo
Description: Patients wear the placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.